AI Article Synopsis
- The systematic review analyzed the effects of oral fluconazole on major congenital malformations (MCM) and miscarriages during the first trimester of pregnancy, including nine studies with over 3.7 million pregnancies.
- Findings indicated that while crude estimates suggested a slight increase in overall MCM risk with fluconazole use, adjusted estimates showed no significant association, particularly for subtypes of MCM.
- A notable link was found between fluconazole use and miscarriages, especially at doses exceeding 150 mg, highlighting the need for cautious use during early pregnancy despite the overall low risk for MCM.
Article Abstract
The risks related to fluconazole use during the first trimester of pregnancy (T1) remain controversial. The aims of this systematic review and meta-analysis were to assess the association between oral fluconazole during T1 and major congenital malformations (MCM) overall and by subtype, minor malformations and miscarriages.We searched MEDLINE, EMBASE, Cochrane, ICTRP and ClinicalTrials.gov from inception to 02/12/24. Randomized controlled trials and observational studies were included. ROBINS-I was used for risk of bias assessment. Both fixed- and random-effects models meta-analyses were performed. GRADE was used to assess the certainty of the evidence.Among 1403 references, nine observational studies were included (3,764,897 pregnancies, including 116,425 exposed to fluconazole). The association between any fluconazole use during T1 and overall MCM was significant when combining crude estimates (ORc 1.18, 95%CI (1.08-1.29), I 23%, seven studies), but not when combining adjusted estimates (ORa 1.02, 95%CI (0.98-1.07), I 0%, six studies). Results were consistent for cumulative dose of fluconazole. In sensitivity analyses considering only studies with a valid definition of MCM, the association between fluconazole > 150 mg and overall MCM remained significant when combining adjusted estimates. For the subtypes of MCM (cardiac, genito-urinary, musculoskeletal) we found no significant association. A significant association was found between fluconazole use and miscarriages (ORa 1.60, 95% CI (1.06-2.42).Fluconazole use during T1 does not significantly increase the risk of MCM overall or by subtype when considering adjusted estimates. However, potential risks, particularly at cumulative doses greater than 150 mg which show a potential association with MCM, deserve much attention.PROSPERO Registration The protocol was registered on the 23rd September 2021 (registration number: CRD42021274003).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10654-024-01177-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inter-Institutional Dynamics and Impact of Fluconazole-Resistant Candida parapsilosis.
Mycoses
January 2025
Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Background: Infections with fluconazole-resistant Candida parapsilosis have been increasing in Israeli hospitals with unclear implications for patient outcomes.
Objectives: To determine the frequency, mechanisms, molecular epidemiology, and outcomes of azole-resistant C. parapsilosis bloodstream infections in four hospitals in Israel.
Perspectives on the Use of Echinocandins in the Neonatal Intensive Care Unit.
Antibiotics (Basel)
December 2024
Neonatal Intensive Care Unit, School of Medicine, University of Ioannina, 45500 Ioannina, Greece.
The neonatal intensive care unit (NICU) population, especially low birth weight and critically ill neonates, is at risk of invasive infections, which are associated with high mortality rates and unfavorable long-term outcomes. The timely initiation of an appropriate antifungal treatment has been demonstrated to enhance the prognosis. Factors that should be considered in the choice of an antifungal agent include the causative strain, the presence and location of deep tissue infection, any previous use of antifungal prophylaxis, and the presence of implanted devices.
View Article and Find Full Text PDFInfection by Trichosporon Inkin in Lung Transplant: Rare Infection, or Not So Rare?
Transplant Proc
January 2025
Lung Transplant Unit, Department of Respiratory Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain.
The incidence of invasive fungal infections has increased in recent years among transplant patients, with Trichosporon inkin being a rare but relevant etiological agent. This study examines the experience of our multidisciplinary lung transplant unit in the diagnosis and treatment of 6 cases of T. inkin infection in transplant patients from 2016 to 2023.
View Article and Find Full Text PDFAntifungal Resistance Patterns of Microsporum canis: A 27-Year MIC Study in Mainland China.
Mycoses
January 2025
Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.
Background: Microsporum canis, a dermatophyte commonly associated with pets, is a leading cause of severe tinea capitis. The increasing prevalence of antifungal resistance among dermatophytes poses a significant global health challenge.
Objectives: This study aims to define the updated antifungal susceptibility profile of M.
Successful Treatment of Primary Acanthamoeba Cutis in a Patient With Chronic Lymphocytic Leukemia on Acalabrutinib.
Am J Dermatopathol
December 2024
Department of Dermatology, Vagelos College of Physician and Surgeons of Columbia University and New York Presbyterian Hospital, New York, NY; and.
Primary cutaneous amoebiasis is rare, and typically affects immunocompromised patients and presents with unique clinical and histopathologic changes. Untreated, the infection could progress to involve the central nervous system, which is almost universally fatal. We present a case of primary cutaneous acanthamoebiasis in a patient with chronic lymphocytic leukemia on acalabrutinib.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!